Zhitong Finance App News, Fosun Pharmaceutical (02196.HK) issued an announcement. Recently, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., a holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the “Company”), submitted a new registration application for furitinib succinate capsules (project code: SAF-189, category 1; hereinafter referred to as “the new drug”) was accepted by the State Drug Administration. The indication for this application is positive for anaplastic lymphoma kinase (ALK) Locally advanced or metastatic non-small cell lung cancer ( NSCLC) treatment of patients.

Zhitong Finance App News, Fosun Pharmaceutical (02196.HK) issued an announcement. Recently, Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd., a holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the “Company”), submitted a new registration application for furitinib succinate capsules (project code: SAF-189, category 1; hereinafter referred to as “the new drug”) was accepted by the State Drug Administration. The indication for this application is positive for anaplastic lymphoma kinase (ALK) Locally advanced or metastatic non-small cell lung cancer ( NSCLC) treatment of patients.